Luminopia

Executive Summary

Luminopia is a digital health company pioneering FDA-cleared binocular therapies for ophthalmic conditions, with its lead product being a prescription digital therapeutic for amblyopia (lazy eye) in children aged 4 to under 13. The therapy employs a virtual reality headset to stream modified television shows, transforming passive viewing into an engaging treatment that improves visual acuity. Founded in 2015 and based in Cambridge, Massachusetts, the company addresses a significant unmet need: amblyopia affects approximately 2-3% of children worldwide, and traditional treatments like patching or atropine drops often suffer from poor compliance. Luminopia's novel approach leverages the neuroplasticity of the developing brain, delivering treatment through a familiar and enjoyable medium, which has the potential to dramatically improve adherence and outcomes. With FDA clearance already achieved, the company is poised to scale commercialization and expand its platform to other binocular vision disorders, positioning itself as a leader in the emerging field of digital therapeutics for ophthalmology.

Upcoming Catalysts (preview)

• Q2 2027Expansion of insurance coverage and reimbursement agreements60% success
• Q4 2027FDA clearance for expanded age range or new indication (e.g., adult amblyopia)40% success
• Q3 2026New partnership or collaboration with major pediatric healthcare network50% success